Hht Foundation International, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1991-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.hht.org
Clinical Trials
3
Active:1
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Comprehensive HHT Outcomes Registry of the United States (CHORUS)
Recruiting
- Conditions
- GastroIntestinal BleedingTelangiectasiaCerebral Arteriovenous MalformationsVascular MalformationEpistaxisHereditary Hemorrhagic TelangiectasiaArteriovenous Malformations
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Cure HHT
- Target Recruit Count
- 10000
- Registration Number
- NCT06259292
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
Phase 2
Active, not recruiting
- Conditions
- Hereditary Hemorrhagic TelangiectasiaNosebleedHHTEpistaxisAnemia
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Cure HHT
- Target Recruit Count
- 70
- Registration Number
- NCT03850964
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸University of Colorado, Denver, Colorado, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia
Phase 1
Not yet recruiting
- Conditions
- Hereditary Hemorrhagic TelangiectasiaEpistaxis
- Interventions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Cure HHT
- Target Recruit Count
- 30
- Registration Number
- NCT03850730
News
No news found